When Vaccine Policy Becomes Market Risk

22 July 2026.

Policy, platforms and manufacturing are reshaping global vaccine market opportunities

The Next Phase of Vaccine Growth

27 May 2026.

Vaccines are shifting from prevention into platforms, oncology and manufacturing-led growth

Vaccine Sales Market Report 2026-2036: 6.3% CAGR

22 May 2026.

The global Vaccine Sales market is projected to grow at a CAGR of 6.3% by 2036

mRNA Vaccines Market Report 2026-2036

14 May 2026.

mRNA vaccine platforms expand beyond prevention into oncology and immune-mediated diseases

mRNA Cancer Vaccine Market Report 2026-2036: 27.1% CAGR

21 April 2026.

The global mRNA Cancer Vaccine market is projected to grow at a CAGR of 27.1% by 2036

The Vaccine Contract Manufacturing Advantage.

12 January 2026.

The global Vaccine Contract Manufacturing market is projected to grow at a CAGR of 10.9% by 2036

mRNA Revolution: the Future of Cancer Care

24 December 2025.

mRNA cancer vaccines advance toward oncology reality, driven by personalisation, combination therapies, scalable manufacturing.

mRNA Contract Manufacturing: The Emergent White Space for CDMOs

10 September 2025.

Scaling fragile mRNA demands advanced CDMO integration, automated quality control, and −80°C infrastructure maturity.

Clients & Partners

BP logo Kelloggs logo BAE systems logo Unilever logo BASF logo 3M logo THALES logo TEVA logo Shell logo Raytheon logo Pfizer logo Lockhead Martin logo Mercedes logo Honeywell logo DUPONT logo Daimler logo Deloitte logo